NFLX:NASDAQNetflix, Inc. Analysis
Data as of 2026-06-02 - not real-time
$85.85
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Netflix is trading just above its short‑term moving average and close to a recently identified support level, while the longer‑term average remains higher, reinforcing a short‑term bearish bias. The 14‑day RSI is in the oversold region, indicating potential for a rebound. The MACD histogram has turned positive, suggesting modest bullish momentum despite the overall bearish trend. Volume has been tapering, pointing to waning buying pressure, and recent volatility remains elevated, implying sizable price swings. Beta is well below the market, which cushions broader market moves, but the current price still trails the discounted cash‑flow fair value by a wide margin, leaving room for upside.
Fundamentally, Netflix delivers strong top‑line growth and robust profitability, with operating margins well above industry norms and an exceptionally high return on equity, underscoring efficient capital deployment. Cash balances comfortably exceed debt, and free cash flow remains healthy, supporting continued investment in content and international expansion. While the trailing P/E is notably higher than the industry average, the forward outlook and analyst consensus remain bullish, bolstered by high‑profile investor endorsement and recent positive earnings commentary. Taken together, the valuation gap, growth profile, and resilient cash generation make the stock an attractive buy for medium‑ to long‑term investors.
Fundamentally, Netflix delivers strong top‑line growth and robust profitability, with operating margins well above industry norms and an exceptionally high return on equity, underscoring efficient capital deployment. Cash balances comfortably exceed debt, and free cash flow remains healthy, supporting continued investment in content and international expansion. While the trailing P/E is notably higher than the industry average, the forward outlook and analyst consensus remain bullish, bolstered by high‑profile investor endorsement and recent positive earnings commentary. Taken together, the valuation gap, growth profile, and resilient cash generation make the stock an attractive buy for medium‑ to long‑term investors.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- price near support with bearish bias
- oversold RSI may trigger a bounce
- decreasing volume signals weakening momentum
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- valuation gap to discounted cash‑flow fair value
- strong cash generation and low leverage
- analyst consensus remains bullish
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- sustained revenue growth and high margins
- global subscriber base diversification
- high return on equity and low debt burden
Key Metrics & Analysis
Financial Health
Revenue Growth16.20%
Profit Margin28.52%
P/E Ratio27.7
ROE48.49%
ROA15.40%
Debt/Equity53.79
P/B Ratio11.6
Op. Cash Flow$12.7B
Free Cash Flow$26.0B
Industry P/E17.0
Technical Analysis
TrendBearish
RSI36.7
Support$85.10
Resistance$92.33
MA 20$87.79
MA 50$92.92
MA 200$101.03
MACDBullish
VolumeDecreasing
Fear & Greed Index92.77
Valuation
Fair Value$158.81
Target Price$114.56
Upside/Downside33.44%
GradeUndervalued
TypeGrowth
Risk Assessment
Beta0.37
Volatility22.65%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.